|
[1] SAPONARO C,GAGGINI M,GASTALDELLI A. Nonalcoholic fatty liver disease and type 2 diabetes:Common pathophysiologic mechanisms[J]. Curr Diab Rep,2015,15(6):607.
|
|
[2] HUMMEL CS,LU C,LOO DD,et al. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2[J]. Am J Physiol Cell Physiol,2011,300(1):c14-c21.
|
|
[3] GAUTAM A,AGRAWAL PK,DONERIA J,et al. Effects of canagliflozin on abnormal liver function tests in patients of type2 diabetes with non-alcoholic fatty liver disease[J]. J Assoc Physicians India,2018,66(8):62-66.
|
|
[4] INOUE M,HAYASHI A,TAGUCHI T,et al. Effects of canagliflozin on body composition and hepatic fat content in type2 diabetes patients with non-alcoholic fatty liver disease[J]. J Diabetes Investig,2019,10(4):1004-1011.
|
|
[5] LAI LL,VETHAKKAN SR,NIK MUSTAPHA NR,et al. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus[J]. Dig Dis Sci,2020,65(2):623-631.
|
|
[6] SEKO Y,NISHIKAWA T,UMEMURA A,et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis[J]. Diabetes Metab Syndr Obes,2018,11:835-843.
|
|
[7] SUMIDA Y,MUROTANI K,SAITO M,et al. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease:A prospective,single-arm trial(LEAD trial)[J]. Hepatol Res,2019,49(1):64-71.
|
|
[8] TOBITA H,SATO S,MIYAKE T,et al. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus:A prospective,open-label,uncontrolled study[J]. Curr Ther Res Clin Exp,2017,87:13-19.
|
|
[9] ARASE Y,SHIRAISHI K,ANZAI K,et al. Effect of sodium glucose co-transporter 2 inhibitors on liver fat mass and body composition in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus[J]. Clin Drug Investig,2019,39(7):631-641.
|
|
[10] SEKO Y,SUMIDA Y,TANAKA S,et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus[J]. Hepatol Res,2017,47(10):1072-1078.
|
|
[11] YAMASHIMA M,MIYAAKI H,MIUMA S,et al. The long-term efficacy of sodium glucose co-transporter 2 inhibitor in patients with non-alcoholic fatty liver disease[J]. Intern Med,2019,58(14):1987-1992.
|
|
[12] ASO Y,KATO K,SAKURAI S,et al. Impact of dapagliflozin,an SGLT2 inhibitor,on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease[J]. Int J Clin Pract,2019,73(5):e13335.
|
|
[13] ERIKSSON JW,LUNDKVIST P,JANSSON PA,et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes:A doubleblind randomised placebo-controlled study[J]. Diabetologia,2018,61(9):1923-1934.
|
|
[14] KUCHAY MS,KRISHAN S,MISHRA SK,et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease:A Randomized Controlled Trial(E-LIFT Trial)[J]. Diabetes Care,2018,41(8):1801-1808.
|
|
[15] SHIBUYA T,FUSHIMI N,KAWAI M,et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease:A prospective randomized controlled pilot study[J]. Diabetes Obes Metab,2018,20(2):438-442.
|
|
[16] ITO D,SHIMIZU S,INOUE K,et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes:A randomized,24-week,open-label,active-controlled trial[J]. Diabetes Care,2017,40(10):1364-1372.
|
|
[17] XUE MM,LI XP,LI Y,et al. Researches advances in sodium-glucose co-transporter 2 inhibitor in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease[J]. J Clin Hepatol,2019,35(12):2812-2816.(in Chinese)薛苗苗，李雪萍，李亚，等．钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病合并非酒精性脂肪肝病的研究进展[J]．临床肝胆病杂志，2019,35(12):2812-2816.
|
|
[18] HAYASHIZAKI-SOMEYA Y,KUROSAKI E,TAKASU T,et al.Ipragliflozin,an SGLT2 inhibitor,exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats[J]. Eur J Pharmacol,2015,754:19-24.
|
|
[19] QIANG S,NAKATSU Y,SENO Y,et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus[J]. Diabeto Metab Syndr,2015,7(1):104.
|
|
[20] SHIMIZU M,SUZUKI K,KATO K,et al. Evaluation of the effects of dapagliflozin,a sodium-glucose co-transporter-2 inhibitor,on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease[J]. Diabetes Obes Metab,2019,21(2):285-292.
|
|
[21] TAHRANI AA,BARNETT AH,BAILEY CJ. SGLT inhibitors in management of diabetes[J]. Lancet Diabetes Endocrinol,2013,1(2):140-151.
|
|
[22] SCHEEN AJ. Reduction in HbA1c with SGLT2 inhibitors vs.DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c:A systematic review of randomized controlled trials[J]. Diabetes Metab,2020,46(3):186-196.
|
|
[23] YU X,WANG WJ,JIN JY,et al. Linggui Zhugan Decoction combined with probiotics in the treatment of nonalcoholic fatty liver disease[J]. J Changchun Univ Chin Med,2019,35(5):891-894.(in Chinese)喻晓，王雯婕，金嘉悦，等．苓桂术甘汤联合益生菌治疗非酒精性脂肪肝[J]．长春中医药大学学报，2019,35(5):891-894.
|
|
[24] HERMANSEN K,MORTENSEN LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus[J]. Drug Saf,2007,30(12):1127-1142.
|
|
[25] KOWDLEY KV,BELT P,WILSON LA,et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J].Hepatology,2012,55(1):77-85.
|
|
[26] WANG LN,ZHOU L. Effect observation of SLGT-2 inhibitor on serum leptin level in patients with diabetic fatty liver disease[J]. Clin J Chin Med,2019,11(30):49-50.(in Chinese)王丽娜，周林．SLGT-2抑制剂在糖尿病脂肪肝患者的治疗中对血清瘦素水平的作用观察[J]．中医临床研究，2019,11(30):49-50.
|
DownLoad: